Tonix's lead drug fails PhI­II again, send­ing stock even clos­er to ze­ro

When lit­tle Tonix Phar­ma­ceu­ti­cals re­vealed last Ju­ly that its lead drug failed an in­ter­im analy­sis in fi­bromyal­gia — so much so that out­side da­ta mon­i­tors rec­om­mend­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER